Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Proposed off-market purchase alongside Pfizer

18th Mar 2025 16:51

RNS Number : 1787B
Haleon PLC
18 March 2025
 

 

Haleon plc: Proposed off-market purchase alongside Pfizer Inc. offering

 

18 March 2025: Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) notes the announcement today by Pfizer Inc. ("Pfizer") of its proposed offering of ordinary shares of £0.01 each in the Company to institutional investors by way of an accelerated bookbuild offering process (the "Proposed Offering").

 

Haleon has agreed with Pfizer to make an off-market purchase of approximately £170 million worth of ordinary shares from Pfizer, subject to (a) the offering price per ordinary share in the Proposed Offering (the "Share Offering Price") being no more than the price per ordinary share as at close of trading today on the main market of the London Stock Exchange, and (b) completion of the Proposed Offering.

 

Subject to completion of the off-market purchase, the purchase price per ordinary share to be paid by Haleon to Pfizer will be equal to the Share Offering Price.

 

The off-market purchase will represent a portion of the £500 million allocated to share buybacks in 2025 announced on 27 February 2025. Haleon intends to cancel the purchased ordinary shares.

 

Further details will be provided following announcement by Pfizer of the results of the Proposed Offering.

 

Amanda Mellor 

Company Secretary 

 

 

Enquiries

 

Investors

Media

 

Jo Russell

+44 7787 392441

Zoë Bird

+44 7736 746167

Rakesh Patel

+44 7552 484646

Victoria Durman

+44 7894 505730

Emma White

+44 7823 523562

 

Email: [email protected]

 

Email: [email protected]

 

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.

 

For more information please visit www.haleon.com

 

 

Not for release, publication or distribution in the United States, Canada, Japan, Australia or any other state or jurisdiction in which such release, publication or distribution would be unlawful.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCQVLFFEXLZBBV

Related Shares:

Haleon
FTSE 100 Latest
Value8,666.12
Change-23.47